NEW YORK, November 11, 2016 /PRNewswire/ --
Pre-market, Stock-Callers.com reviews the performances of the followingGeneric Drugs companies: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lannett Co. Inc. (NYSE: LCI), The Medicines Co. (NASDAQ: MDCO), and SCYNEXIS Inc. (NASDAQ: SCYX). According to a report released by IMARC Group last October, the U.S. generic market
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s stock finished Thursday's session 2.48% higher at $16.53. A total volume of 3.07 million shares was traded, which was above their three months average volume of 1.21 million shares. The Company's shares have advanced 14.87% in the past month, 23.73% in the previous three months, and 42.62% on an YTD basis. The stock is trading 14.53% and 34.19% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Ironwood Pharmaceuticals, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 72.89.
On November 03rd, 2016, Ironwood Pharmaceuticals reported that collaborative arrangements revenue was $66.1 million in Q3 2016 compared to $39.6 million in Q3 2015. Included in collaborative arrangements revenue was $60.0 million associated with Ironwood's share of the net profits from the sales of LINZESS in the U.S., up from $34.8 million in Q3 2015. The company's GAAP net loss was $33.2 million, or $0.23 per share, in the reported quarter compared to $47.4 million, or $0.33 per share, in Q3 2015.
On November 04th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $19 a share to $20 a share. Access our complete research report on IRWD for free at:
On Thursday, shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. recorded a trading volume of 1.44 million shares, which was higher than their three months average volume of 1.28 million shares. The stock ended the session 10.10% higher at $22.35. The Company's shares are trading 10.27% below their 200-day moving average. Moreover, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 48.52.
On November 03rd, 2016, Lannett reported that net sales increased 52% to $161.6 million for Q1 FY17 from $106.4 million in Q1 FY16. Gross profit as a percentage of net sales was 51% compared to 73% in Q1 FY16. Net loss attributable to Lannett was $29.4 million, or $0.80 per share, in Q1 FY 17 compared to net income attributable to Lannett of $33.2 million, or $0.89 per diluted share, for Q1 FY16. The complimentary research report on LCI can be downloaded at:
Shares in Parsippany, New Jersey-based The Medicines Co. closed the day 1.69% higher at $35.00. The stock recorded a trading volume of 1.66 million shares, which was higher than its three months average volume of 1.13 million shares. The Company's shares are trading 0.96% below their 200-day moving average. Additionally, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 50.86.
On November 07th, 2016, Medicines Co. announced the immediate discontinuation of the clinical development program for MDCO-216, its investigational cholesterol efflux promoter. The company noted that data from the recently-completed MILANO-PILOT trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development. The safety profile of MDCO-216 was excellent.
On November 08th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $48 a share to $45 a share. Register for free on Stock-Callers.com and get access to the latest PDF format report on MDCO at:
At the close, shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. ended at $3.61, jumping 6.80%. The stock recorded a trading volume of 681,630 shares. The Company's shares have surged 67.13% in the previous three months. The stock is trading above its 200-day moving average by 2.84%. Furthermore, shares of SCYNEXIS, which develops and commercializes novel anti-infectives to address unmet therapeutic needs, have an RSI of 54.45.
On October 20th, 2016, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, issuing a target price of $14 per share.
On November 07th, 2016, SCYNEXIS reported that loss from operations for Q3 2016 was $6.7 million compared to a loss from operations of $7.5 million for Q3 2015. Cash, cash equivalents, and investments totaled $58.4 million as of September 30th, 2016, including $15 million from the Solar Capital term loan. Download your free research report on SCYX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All